575 - AI-based methods for nuclear-medicine imaging: Need for objective task-specific evaluation (ID 256) - Society of Nuclear Medicine and Molecular Imaging 2020 Annual Meeting

575 - AI-based methods for nuclear-medicine imaging: Need for objective task-specific evaluation (ID 256)

Physics, Instrumentation & Data Sciences -> Image Generation 575

575 - AI-based methods for nuclear-medicine imaging: Need for objective task-specific evaluation (ID 256)

Session Name

SPECT, Image Quality, Therapy

Speakers

Z. Yu

Authors

Presentation Topic

Physics, Instrumentation & Data Sciences -> Image Generation

Presentation Number

575

Previous Eposter

574 - Deep Learning Based 3D Dose Estimation from Prompt Gamma Distribution for Proton Therapy Monitoring (ID 259)

Next Eposters

576 - 3D Structural Convolutional Sparse Coding for PET Image Reconstruction (ID 258)

577 - Data-driven respiratory signal estimation from finely sampled projection data in conventional cardiac perfusion SPECT imaging. (ID 253)

580 - Evaluation of Methods to Decrease Formation of a Higher Molecular Weight Species When²¹¹At-Labeling of Antibody-B10 Conjugates Using Chloramine-T as Oxidant (ID 1244)

581 - N-(Maleimidoethyl)-3-(guanidinomethyl)-5-[¹³¹I]iodobenzmide ([¹³¹I]MEGMIB): A Residualizing Prosthetic Agent for Site-Specific Radioiodination of Internalizing Single Domain Antibody Fragments. (ID 1243)

583 - Nucleophilic radiofluorination of aryl halides with K¹⁸F mediated by well-defined copper complexes (ID 1242)

585 - ¹⁸F-Radiofluorination of Aryl C-H Bonds using a Tandem Ir C-H Borylation/Cu Radiofluorination Strategy (ID 1241)

586 - A general ¹¹C-carboxylation approach mediated by fluoride-desilylation of organosilanes (ID 1239)

587 - MACROPA highly stable chelator of Radium-223 and functionalization attempts for targeted treatment of cancer (ID 1246)

588 - ¹⁷⁷Lu-EB-PSMA radioligand therapy with escalating doses in patients with metastatic castration-resistant prostate cancer (ID 771)

590 - Interim Assessment of Kidney Dosimetry and Pharmacokinetics in a Phase I Study of CTT1403, a novel ¹⁷⁷Lu-labeled Small Molecule Inhibitor of Prostate Specific Membrane Antigen (ID 773)